Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Tong Ren Tang Technologies Co (TGRNF) fair value: what the stock is really worth
As of Jul 2, 2026: fair value of Tong Ren Tang Technologies Co $0.99, price $0.49, upside +100.0%, quality 65 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
TR
Thin data
Sep 24, 2026
Thin data
Sep 24, 2026
Tong Ren Tang Technologies Co
TGRNF · USClearly undervaluedStrong Fair Value upside, but quality is only moderate.
✓Fair value $0.9900 · Strongly undervalued (+100.0%)
✓Quality 65/100
!Mixed Growth (revenue 5y +6.5 %/yr)
!Thin margins · 6.1% net margin (TTM)
✓Low debt · generates free cash flow
!Narrow moat 38/100
!Evidence only low, so the estimate is less certain
Watch Tong Ren Tang Technologies Co for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Sep 24, 2026.
How to read this chart
60‑month range $0.4940 – $1.35 · fair‑value band $0.7400 – $1.24 · the $0.4949 price screens below the $0.9900 fair value. As of Sep 24, 2026.
Company profile
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others.
Show more
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through three segments: The Company; Tong Ren Tang Chinese Medicine; and Others. The company develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products. It also offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In addition, it provides medical research and development; advertisement; and Chinese medical consultations and treatments. Further, the company produces and processes biochemical products; extracts and processes plants; and offers medical services. Tong Ren Tang Technologies Co. Ltd. was founded in 1669 and is based in Beijing, the People's Republic of China.
Stock analysis
Tong Ren Tang Technologies Co (TGRNF) currently trades at $0.4949, while our model-based Fair Value estimate is $0.9900, implying the stock looks roughly 50.0% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of $2.22 per share, and 22 of the 26 models we run sit above the $0.4949 price.
Bear case: the Dividend Discount group reads lowest at $0.3400, and 4 of the 26 models stay below the price. Evidence for this calculation is low.
Scenario range: $0.7400 (bear) to $1.24 (bull), the price of $0.4949 sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 65/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Tong Ren Tang Technologies Co reported revenue of 6.3B CNY in FY2025 versus 5.4B CNY in FY2021, a compound +4.0%/yr. Reported net income was 386M CNY in FY2025, compounding −6.6%/yr from FY2021.
Key figures
Market cap $634M · P/E ratio 9.9 · P/S ratio 0.60 · EPS (TTM) $0.0500 · Net margin 6.1% · Return on equity 6.5% · Return on assets (EBIT) 8.0% · Operating margin 8.5%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 42 out of 100 (low confidence).
What moves the price
For context, the median of 10 Healthcare peers we cover trades at −1% fair-value upside, at 100%, TGRNF screens cheaper than that median.
Fair Value models
Bear $0.7400
Fair Value $0.9900
Bull $1.24
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$2.13
$3.14
$4.61
79
Growth DCF
$2.12
$3.04
$4.30
77
Owner Earnings
$1.14
$1.58
$2.22
76
All 26 models by family
DCF Models
FCF DCF
$2.13
$3.14
$4.61
79
Owner Earnings
$1.14
$1.58
$2.22
76
5Y Revenue Exit
$1.55
$2.14
$2.89
72
5Y EBITDA Exit
$1.81
$2.66
$3.68
74
5Y P/E Exit
$1.46
$1.97
$2.52
71
10Y Revenue Exit
$1.74
$2.33
$3.14
67
10Y EBITDA Exit
$1.92
$2.67
$3.72
68
10Y P/E Exit
$1.71
$2.22
$2.86
64
Earnings-Based
Graham-Dodd
$0.3100
$1.23
$1.68
61
Lynch FV
$0.3100
$0.4400
$0.5700
58
PEG = 1.0
$0.3100
$0.4400
$0.5700
55
EPV
$0.9600
$1.04
$1.11
72
Dividend Discount
Gordon GGM
$0.2100
$0.3700
$0.5100
65
DDM Multi-Stage
$0.2100
$0.3400
$0.4000
65
Multiples
P/E Multiple
$0.7400
$0.9900
$1.24
61
P/S Multiple
$0.5700
$0.7600
$0.9600
56
P/B Multiple
$0.5700
$0.7600
$0.9600
53
EV/EBIT
$1.55
$1.93
$2.32
65
EV/EBITDA
$1.75
$2.20
$2.66
66
EV/Revenue
$1.21
$1.57
$1.93
53
Asset-Based
NCAV (Graham)
$0.4300
$0.5700
$0.8600
52
Growth DCF
Growth DCF
$2.12
$3.04
$4.30
77
Rev-Margin DCF
$1.55
$2.15
$2.90
72
Economic Profit
Residual Income
$0.6300
$0.6300
$0.6600
75
ROIC Compounder
$1.00
$1.15
$1.34
71
Growth Earnings
Growth-Adj P/E
$0.5500
$0.7900
$1.03
66
Notify me when TGRNF reaches fair value
Put TGRNF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
65/100
Of which business quality 67 · Market factors (momentum, volatility) 12
Profitability
31
Margins and returns on capital today
Quality Growth
27
Are margins and returns improving?
Cashflow
94
Earnings quality: real cash, not paper profit
Fin. Strength
80
Balance sheet, leverage, solvency risk
Investment
88
Disciplined investing over empire-building
Low Volatility
39
Calm price path (market factor)
Momentum
0
Price trend over the last 3–12 months (market factor)
52W Momentum
0
Distance to the 52-week high (market factor)
Net Issuance
82
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
66/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−13.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
Start year 2020 (pandemic). Over 10 years: +4.5% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−3.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.8%
Dividend (yield on the price)0.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−3.8% vs −3.3%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.21% → 12%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
less than -40 %
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
Watch TGRNF, get fair value alerts →
Compare Tong Ren Tang Technologies Co with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 73 stocks
Beats the industry median on 4/10 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Amgen Inc AMGN | $421.51 | $463.66 | +10% |
| Gilead Sciences, Inc GILD | $149.05 | $198.77 | +33% |
| Pfizer Inc PFE | $28.12 | $24.87 | −12% |
| Bristol-Myers Squibb Company BMY | $62.40 | $75.96 | +22% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Tong Ren Tang Technologies Co (TGRNF) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $0.9900 versus the last price from Jul 2, 2026 of $0.4949, about +100% upside (undervalued).
What is the fair value of TGRNF?
Our model-based fair value for Tong Ren Tang Technologies Co is $0.9900 (as of Sep 24, 2026), built from audited fundamentals. Last price (from Jul 2, 2026): $0.4949.
What is the quality score of TGRNF?
Tong Ren Tang Technologies Co has a Quality Score of 65/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Tong Ren Tang Technologies Co (TGRNF)?
Our model-based price target is the fair value of $0.9900 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $0.7400, optimistic scenario $1.24. It is a calculation from audited fundamentals, not an analyst target.
What is the Tong Ren Tang Technologies Co stock forecast for 2026?
Our models put fair value at $0.9900, about +100% upside versus the last price from Jul 2, 2026 of $0.4949 (undervalued). Cautious scenario $0.7400, optimistic scenario $1.24. The calculation is refreshed regularly with new filings.
What is the revenue of Tong Ren Tang Technologies Co (TGRNF)?
Tong Ren Tang Technologies Co reported trailing-twelve-month revenue of about 6.5B CNY (latest available figure, as of Sep 24, 2026).
What growth is priced into Tong Ren Tang Technologies Co (TGRNF)?
For today's price to be fair in a discounted-cash-flow model, Tong Ren Tang Technologies Co would have to grow free cash flow by less than minus 40 % per year for five years (discount rate 10.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.5 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of TGRNF use?
Our models discount Tong Ren Tang Technologies Co at 10.6 %: a base by market capitalisation (small), damped by beta 0.78, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Tong Ren Tang Technologies Co that is less than minus 40 % per year a year over ten years, using the same discount rate (10.6 %) and the same formula as our fair value.
How much growth has Tong Ren Tang Technologies Co (TGRNF) delivered so far?
Over the past 5 years revenue at Tong Ren Tang Technologies Co grew +6.5 % a year. The price currently implies less than minus 40 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Tong Ren Tang Technologies Co (TGRNF) growing?
The median revenue growth in the sector is +5.2 % a year. That is the yardstick for the growth priced into Tong Ren Tang Technologies Co (less than minus 40 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Tong Ren Tang Technologies Co (TGRNF)?
The free-cash-flow yield on the price is 34.02 %: that much free cash flow Tong Ren Tang Technologies Co produces per unit of market value. When it exceeds the discount rate of our models (10.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Tong Ren Tang Technologies Co (TGRNF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Tong Ren Tang Technologies Co it is $0.9900 per share (as of Sep 24, 2026), against a price of $0.4949. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Tong Ren Tang Technologies Co stock overvalued or undervalued in 2026?
As of Sep 24, 2026, TGRNF trades below its calculated fair value: price $0.4949, fair value $0.9900, a gap of about +100% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of TGRNF?
No. The price is what the market pays today ($0.4949); the fair value is what the company's own numbers justify ($0.9900). For Tong Ren Tang Technologies Co the two are $0.4951 per share apart. That gap is exactly why we show both numbers side by side.
How much is Tong Ren Tang Technologies Co worth?
The market values Tong Ren Tang Technologies Co at about $634M (market capitalisation, as of Sep 24, 2026). Per share that is $0.4949; our models calculate a fair value of $0.9900 per share.
What do the bullish and bearish scenarios say about TGRNF?
Our models span a range for Tong Ren Tang Technologies Co: cautious scenario $0.7400, base $0.9900, optimistic $1.24 per share (as of Sep 24, 2026, price $0.4949). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of TGRNF?
Tong Ren Tang Technologies Co trades at a price-to-earnings ratio of 9.9 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $0.9900 is built from several models across several years.
How solid is the balance sheet of Tong Ren Tang Technologies Co (TGRNF)?
Balance-sheet figures for Tong Ren Tang Technologies Co (as of Sep 24, 2026): return on equity 6.5%, debt of 0.20 per unit of equity. They feed the Quality Score of 65/100, which measures business quality independently of the share price.
Which stocks are comparable to Tong Ren Tang Technologies Co?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Tong Ren Tang Technologies Co stock attractive at the current price?
The data as of Sep 24, 2026: price $0.4949, calculated fair value $0.9900 (+100%), Quality Score 65/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of TGRNF calculated?
We run Tong Ren Tang Technologies Co through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.9900, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Tong Ren Tang Technologies Co currently trades 50 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Tong Ren Tang Technologies Co (TGRNF)?
The latest price we hold is from Jul 2, 2026 and stands at $0.4949. Our model-based fair value is $0.9900, about +100% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Tong Ren Tang Technologies Co right now?
The price is below even our cautious bear case ($0.7400). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (65/100) at a price below fair value, the discount is the argument here, not the business quality.
Where does the earnings growth of Tong Ren Tang Technologies Co (TGRNF) come from?
Earnings per share at Tong Ren Tang Technologies Co grew −0.7 % a year from 2014 to 2025. Broken into its drivers: revenue per share +6.0 %, EBIT margin −4.5 %, tax rate −0.4 %, residual (interest, one-offs) −1.4 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Tong Ren Tang Technologies Co
How large is the market capitalisation of Tong Ren Tang Technologies Co (TGRNF)?
The market capitalisation of Tong Ren Tang Technologies Co is $634M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Tong Ren Tang Technologies Co (TGRNF)?
The price-to-sales ratio of Tong Ren Tang Technologies Co is 0.60 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Tong Ren Tang Technologies Co (TGRNF)?
Earnings per share at Tong Ren Tang Technologies Co are $0.0500 (price ÷ EPS = P/E 9.9). Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Tong Ren Tang Technologies Co (TGRNF)?
The net margin of Tong Ren Tang Technologies Co is 6.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Tong Ren Tang Technologies Co (TGRNF)?
The return on equity (ROE) of Tong Ren Tang Technologies Co is 6.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Tong Ren Tang Technologies Co (TGRNF)?
On an EBIT basis the return on assets of Tong Ren Tang Technologies Co is 8.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Tong Ren Tang Technologies Co (TGRNF)?
The operating margin of Tong Ren Tang Technologies Co is 8.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Tong Ren Tang Technologies Co (TGRNF)?
Revenue at Tong Ren Tang Technologies Co is growing −14.5% versus a year earlier (3y avg +1.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Tong Ren Tang Technologies Co (TGRNF)?
Earnings per share at Tong Ren Tang Technologies Co are growing −38.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Tong Ren Tang Technologies Co (TGRNF) hold?
Tong Ren Tang Technologies Co holds more cash than debt, 2.7B CNY net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Tong Ren Tang Technologies Co in the live analysis
One click puts Tong Ren Tang Technologies Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.